Description
Rearranged during transfection (Ret) is a receptor tyrosine kinase that governs cell growth, survival, and differentiation. Upon activation by glial cell line-derived neurotrophic factor (GDNF) family ligands, Ret triggers downstream signaling cascades, including MAPK, PI3K/AKT, and JAK/STAT. Ret fusions and activating mutations drive oncogenesis in thyroid cancer, lung adenocarcinoma, and multiple endocrine neoplasia (MEN) syndromes, making it a key target for precision therapies.
The AlphaLISA SureFire Ultra Human Phospho-Ret (Tyr905) Detection Kit is a sandwich immunoassay for the quantitative detection of phospho-Ret (Tyr905) in cellular lysates, using Alpha Technology.
Formats:
The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.
AlphaLISA SureFire Ultra kits are compatible with:
Cell and tissue lysates
Antibody modulators
Biotherapeutic antibodies
AlphaLISA SureFire Ultra kits can be used for:
Cellular kinase assays
Receptor activation studies
High-throughput screening for preclinical studies
Phospho-AlphaLISA SureFire Ultra assay principle
The Phospho-AlphaLISA SureFire Ultra assay measures a target protein when phosphorylated at a specific residue in a biological sample (e.g. cell lysate).
The assay uses two antibodies which recognize the phospho epitope and a distal epitope on the target protein. AlphaLISA assays require two bead types: Acceptor and Donor Beads. Acceptor Beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor Beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor Beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor Bead, allowing for the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of phosphoprotein present in the sample.
Phospho-AlphaLISA SureFire Ultra two-plate assay protocol
The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Phospho-AlphaLISA SureFire Ultra detection reagents. This protocol enables cell viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.
Phospho-AlphaLISA SureFire Ultra one-plate assay protocol
Detection of Phosphorylated target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining robust AlphaLISA SureFire Ultra quality.
GDNF activation of Ret Phospho (Tyr905)
MCF7 cells were seeded in a 96-well plate (40,000 cells/well) in complete media, and incubated overnight at 37°C, 5% CO2. The cells were then starved overnight in serum-free media and treated with increasing concentrations of GDNF for 15 minutes.
After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Ret Phospho (Tyr905) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, GDNF triggered a dose-dependent increase in the levels of Ret Phospho (Tyr905) while Ret Total levels remained unchanged.
Activation of Ret Phospho (Tyr905) in cells treated with pervanadate
SH-SY5Y cells were seeded in a 96-well plate (40,000 cells/well) and incubated overnight at 37°C, 5% CO2. The cells were treated with 12.5 µM Retinoic Acid for 18 hours and then increasing concentrations of pervanadate for 30 minutes.
After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Ret Phospho (Tyr905) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, pervanadate caused a dose-dependent increase in the levels of Ret Phospho (Tyr905) while Ret Total levels remained unchanged.
